A phase 3 clinical trial investigated the oral JAK inhibitor povorcitinib for the treatment of nonsegmental vitiligo.

What it means

This is a Nature Medicine paper reporting results from two phase 3 clinical trials (STOP-V1 and STOP-V2) evaluating the oral JAK1 inhibitor povorcitinib (30 mg daily) in adults with nonsegmental vitiligo. The primary endpoint—at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) at week 52—was met by 18.9% of patients versus placebo, showing statistically significant repigmentation. The findings support regulatory applications for povorcitinib in this indication.

Accuracy & sourcesSourced

The claim is highly solid as it comes directly from a peer-reviewed paper in Nature Medicine (primary source). The specific endpoint and response rates are consistent across multiple secondary reports, including conference presentations and press releases from the sponsor Incyte.

How new